Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth CHP Formulary Coverage Update | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    Formulary — Covered Outpatient Drugs (CHP)

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists outpatient prescription drugs covered under EmblemHealth CHP plans (formulary updated May 1, 2026) and explains coverage features such as prior authorization, quantity limits, step therapy, specialty designation, and how members/providers can get help.

    Policy Summary
    PayerEmblemHealth
    PolicyFormulary — Covered Outpatient Drugs (CHP)
    Policy CodePolicy N/A
    Change TypeFormulary update (no material changes)
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug's Requirements/Limits entry lists 'PA' to avoid denial of coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    May 1, 2026effective
    Home delivery availablemail-order
    PA/QL/LA/SPutilization controls
    ~160+distinct entries
    20+specialty products

    Coverage Criteria and General Conditions

    General coverage conditions

    Covered when ALL of the following are met:

    Formulary coverage prerequisites: Drug must be on the plan formulary (Drug Tier indicated) and coverage is subject to plan rules and member benefit limitations

    Check member's Certificate of Coverage and contact member services for plan-specific coverage and cost-sharing confirmation (see member ID).

    Utilization management satisfied: Any utilization management controls listed for the drug (e.g., PA, QL, ST, LA, SP) must be satisfied prior to coverage

    If prior authorization (PA) is required and not obtained, the plan may not cover the drug; quantity limits (QL) and step therapy (ST) must be followed per the Requirements/Limits entry.

    Coverage controls (administrative)

    Coverage and controls indicated by annotation — drugs are covered subject to the following conditions when the annotation is present:

    Policy Summary
    PayerEmblemHealth
    PolicyFormulary — Covered Outpatient Drugs (CHP)
    Policy CodePolicy N/A
    Change TypeFormulary update (no material changes)
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug's Requirements/Limits entry lists 'PA' to avoid denial of coverage.
    SourceLink
    On This Page
    Coverage Criteria and General ConditionsFormulary Listings and Coding / Drug TablesProvider Requirements, Prior Authorization, and DocumentationQuantity Limits (Per-Product Examples)Specialty Pharmacy and Site-of-Care DesignationsBiosimilars and Related NotesDefinitions and AcronymsStep Therapy Requirements and Starter PacksBackground and Scope
    Administrative controls (apply as annotated): If a formulary entry lists 'PA' the drug requires prior authorization; if 'QL' the specified quantity limit applies; if 'SP' the drug is managed as a specialty product; if 'LA' or 'ACA' additional limited-access or ACA-related rules apply.

    Apply payer-specific PA, QL, LA and SP procedures as published; supporting documentation must be submitted when these flags are present.

    Specialty and limited-access items: Drugs annotated with 'SP' and/or 'LA' are subject to specialty distribution or limited access processes and typically require PA and supporting clinical documentation for coverage.

    Examples in the formulary show many oncology and biologic agents with LA/PA/QL/SP annotations (see Requirements/Limits entries).

    General coverage conditional on utilization controls

    Coverage for listed drugs is conditional on meeting the formulary controls shown inline:

    Formulary coverage conditions: Coverage requires: (1) the drug appears on the plan formulary (tier indicated); AND (2) any listed utilization control (PA, QL, LA, SP, ST) is satisfied per the Requirements/Limits entry; AND (3) the quantity dispensed does not exceed the QL unless an authorization or exception is approved.

    Examples: inhalers and specialty biologics in the list show QL values (e.g., QL (1 inhaler/30 days), QL (3 inhalers/30 days), biologics with QL in syringes/pens per period) and some items carry ST (step therapy) requirements.

    A medicine appearing on this formulary does not guarantee payment under every EmblemHealth drug benefit. Not all drugs listed are paid for by all drug benefit plans; coverage, copays, and other rules vary by member plan. Members and prescribers should check the member’s Certificate of Coverage or contact Member Services to confirm whether a specific drug, strength, or quantity is covered and what cost-sharing or prior authorization requirements apply.

    Many entries in this segment show a Drug Tier = 1 and are presented without an accompanying utilization-control flag. When an entry has no PA/QL/LA/ACA/SP annotation, it is listed as Tier 1 in the formulary and no additional prior authorization, quantity limit, limited-access, ACA, or specialty flag is shown in the Requirements/Limits field for that line-item.

    Within the provided excerpt there are no explicit clinical exclusion conditions stated. The lines here list products with formulary tier and any Requirements/Limits flags; any explicit exclusions, if present, are documented elsewhere in the full policy or Certificate of Coverage.

    The document segment primarily lists formulary entries and their utilization management controls (e.g., PA, QL, LA, SP, ST) alongside each product. These entries present administrative formulary controls and dispensing limits rather than detailed clinical medical‑necessity criteria.

    When a product’s Requirements/Limits field includes flags such as PA, QL, LA, or SP, that annotation identifies a payer requirement that must be satisfied for coverage. Failure to obtain required prior authorization or to comply with quantity limits or other listed controls may result in the plan denying payment for that drug.

    Formulary Listings and Coding / Drug Tables

    Covered outpatient drug listings (examples)mixedCovered
    amoxicillin (trihydrate) tab 500 mg, 875 mgAmoxicillin tablet dosages listed; Drug Tier = 1
    amoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mgAmoxicillin-clavulanate tablet dosages listed; Drug Tier = 1
    cefuroxime axetil tab 250 mg, 500 mgCefuroxime axetil tablets; Drug Tier = 1
    azithromycin tab 250 mg, 500 mg, 600 mg; susp 100 mg/5ml, 200 mg/5ml (Zithromax)Azithromycin formulations; Drug Tier = 1
    clarithromycin for susp 125 mg/5ml, 250 mg/5ml; tab 250 mg, 500 mgClarithromycin formulations; Drug Tier = 1
    fidaxomicin tab 200 mg (Dificid)Fidaxomicin listed; Drug Tier = 1
    doxycycline, minocycline, omadacycline (NUZYRA)Tetracycline-class agents listed; Drug Tier = 1 (NUZYRA marked LA)
    ciprofloxacin, levofloxacin, moxifloxacin, ofloxacinFluoroquinolones listed; Drug Tier = 1
    BAXDELA - delafloxacin meglumine tab 450 mgDelafloxacin listed; Drug Tier = 1
    Drug list (no billing codes)mixed
    N/ANo CPT/HCPCS/ICD-10 codes provided in this section; entries are drug names with form and dose.
    Formulary drug entries (brands and generics) in this segmentmixed
    IWILFINeflornithine hcl tab 192 mg
    JAKAFIruxolitinib phosphate tab 5 mg, 10 mg, 15 mg, 20 mg, 25 mg (base equivalent)
    JAYPIRCApirtobrutinib tab 50 mg, 100 mg
    KISQALIribociclib succinate tab pack 200 mg, 400 mg, 600 mg daily dose
    KOSELUGOselumetinib sulfate cap 10 mg, 25 mg
    KRAZATIadagrasib tab 200 mg
    LAZCLUZElazertinib mesylate tab 80 mg, 240 mg
    LENVIMAlenvatinib cap therapy packs (4 mg up to 24 mg daily doses)
    letrozoleletrozole tab 2.5 mg (Femara)
    leucovorin calciumleucovorin calcium tab 5 mg, 15 mg, 25 mg
    1–10 of 83
    1/9
    Formulary drug entries (excerpt)mixed
    simvastatin tab 80 mgsimvastatin tab 80 mg
    VASCEPA - icosapent ethyl cap 0.5 gmVASCEPA - icosapent ethyl cap 0.5 gm
    VASCEPA - icosapent ethyl cap 1 gmVASCEPA - icosapent ethyl cap 1 gm
    ADEMPAS - riociguat tab 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mgADEMPAS - riociguat tab 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg
    ambrisentan tab 5 mg, 10 mg (Letairis)ambrisentan tab 5 mg, 10 mg (Letairis)
    ATTRUBY - acoramidis hcl tab pack 356 mg (712 mg twice daily)ATTRUBY - acoramidis hcl tab pack 356 mg (712 mg twice daily)
    bosentan tab for oral susp 32 mg (Tracleer)bosentan tab for oral susp 32 mg (Tracleer)
    CAMZYOS - mavacamten cap 2.5 mg, 5 mg, 10 mg, 15 mgCAMZYOS - mavacamten cap 2.5 mg, 5 mg, 10 mg, 15 mg
    CORLANOR - ivabradine hcl oral soln 5 mg/5mlCORLANOR - ivabradine hcl oral soln 5 mg/5ml
    ENTRESTO - sacubitril-valsartan sprinkle cap 6-6 mg, 15-16 mgENTRESTO - sacubitril-valsartan sprinkle cap 6-6 mg, 15-16 mg
    1–10 of 45
    1/5
    Selected product strengths listed in this segmentmixed
    210 mg/1.91mlTEZSPIRE - tezepelumab-ekko subcutaneous solution auto-injector (dosage form/size as listed)
    75 mg/0.5ml, 150 mg/ml, 300 mg/2mlXOLAIR - omalizumab subcutaneous solution (prefilled syringe/pen) (strengths listed)
    100-62.5-25 mcg/actTRELEGY ELLIPTA - fluticasone-umeclidinium-vilanterol (strength/blister)
    80-40-60 mg & ivacaftor 59.5 mg granTRIKAFTA - elexacaftor-tezacaftor-ivacaftor & ivacaftor (various pack forms/strengths)
    108 mg/0.68mlENTYVIO PEN - vedolizumab auto-injector
    inv-14: Quantity Limits examples (general)
    QL examples30 tablets/30 days; 4 tablets/365 days; 28 tablets/28 days; 2 tablets/120 days
    ContextQuantity limits are shown as 'QL (quantity/time period)' next to product entries
    ActionPrescriptions exceeding the stated QL require prior authorization or may be denied
    inv-15: example quantity limit
    Example QLQL (60 tablets/30 days)
    UsageShown inline with specific products (e.g., many oral antivirals and antidiabetics)
    EnforcementClaims must conform to the listed QL or obtain approval
    inv-16: Examples of quantity limits
    240 capsules/30 daysVASCEPA 0.5 g QL = 240 capsules/30 days
    120 capsules/30 daysVASCEPA 1 g QL = 120 capsules/30 days
    90 tablets/30 daysADEMPAS QL = 90 tablets/30 days
    112 tablets/28 daysATTRUBY QL = 112 tablets/28 days
    112 cartridges/28 daysTYVASO DPI maintenance kits QL = 112 cartridges/28 days
    inv-17: Quantity limits examples (inhalers, packets, tablets)
    1 inhaler/30 daysExample QL: 1 inhaler/30 days (e.g., some inhalation products)
    3 inhalers/30 daysExample QL: 3 inhalers/30 days (e.g., SYMBICORT = QL 3 inhalers/30 days)
    56 packets/28 daysExample QL: 56 packets/28 days (e.g., TRIKAFTA packets)
    90 tablets/30 daysExample QL: 90 tablets/30 days (multiple oral products)

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Many drugs listed in this formulary require prior authorization (PA) before the plan will pay. Providers must obtain PA where a drug is labeled PA, and should confirm coverage controls (PA, QL, LA, SP, ST, FF, ACA) for each product before prescribing or dispensing. Failure to obtain required authorizations may result in denial of payment.

    • Prior Authorization Required Where Labeled: If a product entry includes 'PA' the prescriber must request and receive prior authorization before the plan will pay.
    • Prior Authorization Commonly Required: Specialty, oncology, endocrine, biologic, and many GLP-1/GIP agents frequently carry PA requirements and may also have quantity limits (QL), limited access (LA), specialty designation (SP), or step therapy (ST).
    • Prior Authorization and Quantity Limits: Many products are subject to QL; requests for quantities above the stated QL will generally require PA with supporting documentation.
    • Select GLP-1/GIP and Specialty Agents: Examples include MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY — these agents are labeled with PA and QL and often require documentation of medical necessity.
    • Specialty Endocrine Agents: Agents such as GALAFOLD and GENOTROPIN require PA and are often designated SP with QL and LA as noted in product entries.
    • PA for Biologics/Specialty: Biologic agents (eg, TYVASO, NUCALA, FASENRA, TEZSPIRE, many anti‑TNFs and anti‑IL agents) commonly require PA and QL and are designated SP/LA.
    • PA Required for Listed PA Agents: Any product in the formulary annotated with PA requires prior authorization; check the Requirements/Limits column for specifics (QL, LA, SP, ST, FF).
    • PA Required When Indicated: Authorization flags (PA, LA, SP, ST, FF, ACA) in the formulary indicate coverage controls that must be followed to avoid claim denial.
    • Prior Authorization and Step Therapy Present: Some drugs require step therapy (ST) — providers may need to document trials of required agents before PA will be approved.
    • PA Required for Specified Products: Certain stimulants, wakefulness agents (eg, SUNOSI, WAKIX), specialty/DMT agents (eg, AVONEX, BETASERON, cladribine), and others are labeled PA and require prior authorization.
    • PA Required for Listed Specialty Agents: Many specialty immunologic and biologic agents (adalimumab variants, etanercept, abatacept, sarilumab, certolizumab, etc.) are PA and QL labeled — PA must be obtained.
    • Prior Authorization Triggers: PA may be triggered by drug type (specialty, biologic, oncology), formulation (oral solution, starter/titration packs), or when requested quantity exceeds QL.
    Denial Risk

    Utilization Management and Denial Risk

    Utilization management controls (PA, QL, LA, SP, ST, FF, ACA) are enforced across the formulary and may lead to claim denial if requirements are not met. Providers should review the Requirements/Limits column for each product and submit necessary documentation with PA requests.

    • Utilization Management May Trigger Denial: Requests lacking required PA, exceeding QL, or not meeting ST/FF criteria may be denied.
    • Coverage Requirement Indicators: The formulary uses flags (PA, QL, LA, SP, ST, FF, ACA) to indicate required actions — treat these as enforceable controls.
    • PA/QL/LA/SP Presence Indicates Authorization Needed: When any of these flags appear, submit PA with supporting clinical documentation per product-specific requirements.
    • PA/QL and Quantity Limit Risk: Approvals often specify limits (eg, 1 inhaler/30 days, specific pen or syringe counts); exceeding these without authorization risks denial.
    • PA/LA Presence May Trigger Denial: Limited access designations (LA) plus PA frequently indicate restricted distribution or specialty channel requirements; verify prior to dispensing.
    • Denial Triggers — QL/ST/PA: Quantity Limits, Step Therapy, and Prior Authorization are common denial causes if not satisfied.
    Documentation Required

    Provider Actions: Contact, Claims, and Documentation

    Provider actions: contact member services for coverage questions; include complete claim and clinical information when requesting PA; and provide documentation that aligns with the formulary's Requirements/Limits.

    • Contact and Coverage Documentation: Call EmblemHealth Member Services at 877-793-6253 (TTY: 711) for coverage questions and to verify PA processes.
    • Required Claim Information: When submitting a PA or claim, include product name, strength, dose form, quantity, and intended days' supply so the request can be evaluated against Requirements/Limits.
    • Documentation Required When PA/QL/LA/SP Present: Provide clinical notes, prior therapy trials (for ST/FF), lab results, and any specialty documentation requested in product-specific requirements.
    • Required Documentation per Formulary Controls: Follow the Requirements/Limits listed for each product (e.g., QL limits, LA distribution channels, SP handling).
    • Documentation for PA/SP Items: For biologics and specialty drugs include diagnosis, treatment history, weight/dosing information, and any specialty program enrollment details when applicable.
    • Quantity Limits Enforcement and Documentation: If requesting quantities above the stated QL (for example 1 inhaler/30 days or specified pen/syringe limits), submit rationale and supporting clinical evidence.
    Step Therapy

    Step Therapy, Program Restrictions, and Packs

    Step therapy (ST) and program/step restrictions (including fail‑first requirements) apply where noted. Some entries use starter/therapy/titration packs that have their own PA/QL/LA rules. If the formulary shows no explicit ST for a product, limited access (LA) or PA may still apply.

    • Step Therapy / Fail‑First: When ST is listed, the prescriber must document trials of required agents and reasons for failure before PA will approve the requested product.
    • Program/Step Restrictions Noted: Some drugs (eg, APRETUDE, certain LA agents) are flagged with program-level restrictions — follow those program enrollment rules.
    • No Explicit Step Therapy in Excerpt: Absence of ST does not eliminate other controls; LA, PA, or QL may still restrict access.
    • Step Therapy Present for Some Agents: Examples include ferric citrate (FF and ST) and certain psychiatric agents with ST and QL.
    • Step Therapy Requirements When Indicated: Provide documentation of prior drug trials, durations, and outcomes per the ST criteria in Requirements/Limits.
    • Step Therapy Indicated for Specific Agents: Several CNS and GI agents list ST and specific titration/therapy packs that require separate handling.
    • Step/Titration Packs Noted: Starter and titration packs have dedicated QL and PA rules; submit PA referencing the pack when appropriate.
    • Authorization Flags Present: Treat PA, ST, SP, LA, FF annotations as operational requirements — missing authorizations for these flags may lead to denial.

    Quantity Limits (Per-Product Examples)

    inv-122: ARIKAYCE - amikacin sulfate liposome inhalation — 28 vials
    ProductARIKAYCE (amikacin sulfate liposome inhalation)
    Quantity limit28 vials
    Requirements/LimitsLA, PA, QL (28 vials/28 days), SP
    inv-123: itraconazole cap — 120 capsules
    ProductItraconazole capsules (Sporanox) 100 mg
    Quantity limit120 capsules/30 days
    TierDrug Tier = 1
    inv-124: itraconazole oral soln — 1200 mls
    ProductItraconazole oral solution 10 mg/ml
    Quantity limit1200 mls/30 days
    Requirements/LimitsPA, QL (1200 mls/30 days)
    inv-125: SUNLENCA - lenacapavir — 4 tablets
    ProductSUNLENCA (lenacapavir) — tablet therapy pack
    Quantity limit4 tablets (therapy pack), QL (4 tablets/365 days)
    Requirements/LimitsLA, QL (4 tablets/365 days), SP
    inv-126: PAXLOVID pack — 11-30 tablets
    ProductPAXLOVID pack (nirmatrelvir/ritonavir)
    Quantity limit11–30 tablets (pack sizes with QL: 11 tablets/30 days and 20 tablets/30 days examples)
    NotesPack QLs listed per pack configuration (e.g., QL 11 tablets/30 days)
    inv-127: elvitegrav-cobic-emtricitab-tenofovdf — 30 tablets
    ProductElvitegravir‑cobicistat‑emtricitabine‑tenofovir (elvitegrav-cobic-emtricitab-tenofovdf)
    Quantity limit30 tablets/30 days
    TierDrug Tier = 1
    inv-128: SUNLENCA therapy pack — 4 tablets
    ProductSUNLENCA — lenacapavir sodium tablet therapy pack 4 x 300 mg
    Quantity limit4 tablets/365 days (therapy pack)
    Requirements/LimitsLA, QL (4 tablets/365 days), SP
    inv-129: VOSEVI — 28 tablets
    ProductVOSEVI (sofosbuvir‑velpatasvir‑voxilaprevir) 400‑100‑100 mg
    Quantity limit28 tablets/28 days
    Requirements/LimitsPA, QL (28 tablets/28 days), SP
    inv-130: XOFLUZA therapy pack — 2 tablets
    ProductXOFLUZA therapy pack (baloxavir marboxil)
    Quantity limit2 tablets/120 days (therapy pack QL)
    NotesTherapy pack dosing and QL listed with product
    inv-131: YEZTUGO — 4 tablets
    ProductYEZTUGO (lenacapavir) tablet 300 mg
    Quantity limit4 tablets/365 days
    Requirements/LimitsACA, QL (4 tablets/365 days), SP
    inv-132: TRIUMEQ — 30 tablets
    ProductTRIUMEQ (abacavir‑dolutegravir‑lamivudine) 600‑50‑300 mg
    Quantity limit30 tablets/30 days
    NotesQL entries shown per product formulation
    inv-132: TIVICAY — 60 tablets
    ProductTIVICAY (dolutegravir) 50 mg
    Quantity limit60 tablets/30 days
    TierDrug Tier = 1
    inv-134: VIREAD — 30 tablets
    ProductVIREAD (tenofovir disoproxil fumarate)
    Quantity limit30 tablets/30 days
    NotesQL applies to listed strengths/formulations
    inv-135: abiraterone acetate 250 mg — 120 tablets
    ProductAbiraterone acetate 250 mg
    Quantity limit120 tablets/30 days
    Requirements/LimitsPA, QL (120 tablets/30 days), SP
    inv-136: abiraterone acetate 500 mg — 60 tablets
    ProductAbiraterone acetate 500 mg
    Quantity limit60 tablets/30 days
    Requirements/LimitsPA, QL (60 tablets/30 days), SP
    inv-137: BRAFTOVI 75 mg — 180 capsules
    ProductBRAFTOVI (encorafenib) 75 mg
    Quantity limit180 capsules/30 days
    Requirements/LimitsLA, PA, QL (180 capsules/30 days), SP
    inv-138: BRUKINSA 80 mg — 120 capsules
    ProductBRUKINSA (zanubrutinib) 80 mg
    Quantity limit120 capsules/30 days
    Requirements/LimitsLA, PA, QL (120 capsules/30 days), SP
    inv-139: JAKAFI — QL (60 tablets/30 days)
    ProductJAKAFI (ruxolitinib) tablets
    Quantity limitQL (60 tablets/30 days)
    Requirements/LimitsLA, PA, QL (60 tablets/30 days), SP
    inv-140: JAYPIRCA — QL (30 tablets/30 days)
    ProductJAYPIRCA (pirtobrutinib) 50 mg
    Quantity limitQL (30 tablets/30 days)
    Requirements/LimitsLA, PA, QL (30 tablets/30 days), SP
    inv-141: KOSELUGO — QL (120 capsules/30 days)
    ProductKOSELUGO (selumetinib) 25 mg
    Quantity limitQL (120 capsules/30 days)
    Requirements/LimitsLA, PA, QL (120 capsules/30 days), SP
    inv-142: LENVIMA 10 MG DAILY DOSE — QL (30 capsules/30 days)
    ProductLENVIMA 10 mg daily dose (lenvatinib)
    Quantity limitQL (30 capsules/30 days)
    Requirements/LimitsLA, PA, QL (30 capsules/30 days), SP
    inv-143: TAGRISSO — QL (30 tablets/30 days)
    ProductTAGRISSO (osimertinib)
    Quantity limitQL (30 tablets/30 days)
    Requirements/LimitsLA, PA, QL (30 tablets/30 days), SP
    inv-144: VITRAKVI oral soln — QL (300 mls/30 days)
    ProductVITRAKVI (larotrectinib) oral solution
    Quantity limitQL (300 mls/30 days)
    Requirements/LimitsLA, PA, QL (300 mls/30 days), SP
    inv-145: FARXIGA — 30 tablets
    ProductFARXIGA (dapagliflozin)
    Quantity limit30 tablets/30 days
    TierDrug Tier = 1
    inv-146: JANUMET — 60 tablets
    ProductJANUMET (sitagliptin‑metformin)
    Quantity limit60 tablets/30 days
    Requirements/LimitsQL (60 tablets/30 days)
    inv-147: OZEMPIC — 1 pen/28 days or 3 pens/28 days depending on strength
    ProductOZEMPIC (semaglutide) pen
    Quantity limit1 pen/28 days (certain strengths) or 3 pens/28 days (other strength)
    Requirements/LimitsPA, QL per pen strength
    inv-148: MOUNJARO — 4 pens/28 days or 4 pens/180 days (2.5 mg)
    ProductMOUNJARO (tirzepatide) pen injectors
    Quantity limit4 pens/28 days (most strengths) or 4 pens/180 days (2.5 mg)
    Requirements/LimitsPA, QL (as listed)
    inv-149: TRULICITY — 4 pens/28 days (0.75/1.5 mg) or 2 pens/28 days (3/4.5 mg)
    ProductTRULICITY (dulaglutide) pens
    Quantity limit4 pens/28 days (0.75/1.5 mg) or 2 pens/28 days (3 mg/4.5 mg)
    Requirements/LimitsPA, QL per strength
    inv-150: FIASP — 10 vials/30 days or 33 pens/30 days
    ProductFIASP (insulin aspart) vials or pens
    Quantity limit10 vials/30 days or 33 pens/30 days
    Requirements/LimitsQL specified by presentation
    inv-151: LYUMJEV — 10 vials/30 days or 33 pens/30 days
    ProductLYUMJEV (insulin lispro‑aabc)
    Quantity limit10 vials/30 days or 33 pens/30 days
    Requirements/LimitsQL per presentation
    inv-152: INSULIN GLARGINE-YFGN / SEMGLEE — 33 pens/30 days or 10 vials/30 days
    ProductINSULIN GLARGINE‑YFGN / SEMGLEE
    Quantity limit33 pens/30 days or 10 vials/30 days
    Requirements/LimitsQL (pens/vials) as listed
    inv-153: CRENESSITY caps — 60 capsules/30 days
    ProductCRENESSITY capsules
    Quantity limit60 capsules/30 days (capsule form)
    Alternate formOral solution: 120 mls/30 days
    inv-154: CRENESSITY oral soln — 120 mls/30 days
    ProductCRENESSITY oral solution
    Quantity limit120 mls/30 days
    Requirements/LimitsLA, PA, QL (120 mls/30 days), SP
    inv-155: ISTURISA 1 mg — 240 tablets/30 days
    ProductISTURISA (osilodrostat) 1 mg tablets
    Quantity limit240 tablets/30 days
    Requirements/LimitsLA, PA, QL (240 tablets/30 days), SP
    inv-156: ISTURISA 5 mg — 300 tablets/30 days
    ProductISTURISA (osilodrostat) 5 mg tablets
    Quantity limit300 tablets/30 days
    Requirements/LimitsLA, PA, QL (300 tablets/30 days), SP
    inv-157: JYNARQUE — various QL per product (56/28; 60/30; 30/30)
    ProductJYNARQUE (tolvaptan)
    Quantity limitVarious QLs depending on product: 56 tablets/28 days; 60 tablets/30 days; 30 tablets/30 days
    Requirements/LimitsLA, PA, QL per formulation, SP
    inv-158: various examples (propranolol soln, nimodipine soln, REPATHA, NEXLETOL/NEXLIZET, VASCEPA)
    ExamplesPropranolol oral solution QL (4800 mls/30 days); Nimodipine oral soln QL (2520 mls/21 days); REPATHA QL (6 syringes/28 days); NEXLETOL QL (30 tablets/30 days)
    NoteVarious products list product-specific QLs in Requirements/Limits entries
    ActionPrescriptions must follow the specified QL interval or obtain authorization
    inv-159: VASCEPA 0.5 gm — 240 capsules
    ProductVASCEPA icosapent ethyl 0.5 g
    Quantity limit240 capsules/30 days
    Requirements/LimitsPA, QL (240 capsules/30 days)
    inv-160: VASCEPA 1 gm — 120 capsules
    ProductVASCEPA icosapent ethyl 1 g
    Quantity limit120 capsules/30 days
    Requirements/LimitsPA, QL (120 capsules/30 days)
    inv-161: ADEMPAS — 90 tablets
    ProductADEMPAS (riociguat)
    Quantity limit90 tablets/30 days
    Requirements/LimitsLA, PA, QL (90 tablets/30 days), SP
    inv-162: TYVASO inhalation solution 0.6 mg/ml — 7 packages
    ProductTYVASO inhalation solution 0.6 mg/ml
    Quantity limit7 packages/28 days (refill kit QL = 1 kit/28 days in some entries)
    Requirements/LimitsLA, PA, QL (7 packages/28 days), SP
    inv-163: TYVASO DPI maintenance kits — 112 cartridges
    ProductTYVASO DPI maintenance kits
    Quantity limit112 cartridges (maintenance kits) or 224 cartridges/28 days depending on pack
    Requirements/LimitsLA, PA, QL (112 cartridges/28 days), SP
    inv-164: NUCALA auto-injector — 3 pens
    ProductNUCALA auto‑injector (mepolizumab) 100 mg/ml
    Quantity limit3 pens (QL = 3 pens/28 days)
    Requirements/LimitsLA, PA, QL (3 pens/28 days), SP
    inv-165: NUCALA pref syringe 40 mg — 1 syringe
    ProductNUCALA prefilled syringe 40 mg/0.4 ml
    Quantity limit1 syringe (QL = 1 syringe/28 days)
    NotesAlternate presentations have different QLs (e.g., 3 syringes/28 days for other strengths)
    inv-166: TEZSPIRE — 1 pen
    ProductTEZSPIRE (tezepelumab-ekko) 210 mg/1.91 ml pen
    Quantity limit1 pen/28 days (QL = 1 pen/28 days)
    Requirements/LimitsLA, PA, QL (1 pen/28 days), SP
    inv-167: SYMBICORT — 3 inhalers
    ProductSYMBICORT (budesonide‑formoterol)
    Quantity limit3 inhalers/30 days
    Requirements/LimitsQL (3 inhalers/30 days)
    inv-168: TRELEGY ELLIPTA — 60 blisters
    ProductTRELEGY ELLIPTA (100‑62.5‑25)
    Quantity limit60 blisters/30 days (QL = 60 blisters/30 days)
    NotesQL varies by device and strength
    inv-169: TRIKAFTA packets — 56 packets
    ProductTRIKAFTA (packet formulations)
    Quantity limit56 packets/28 days (some pack variants QL = 90 tablets/30 days)
    Requirements/LimitsLA, PA, QL (56 packets/28 days), SP
    inv-170: ENTYVIO PEN — 2 pens
    ProductENTYVIO PEN (vedolizumab) auto‑injector 108 mg/0.68 ml
    Quantity limit2 pens/28 days
    Requirements/LimitsLA, PA, QL (2 pens/28 days), SP
    inv-171: CIMZIA kit — 4 syringes/28 days (starter kit 1 kit/180 days)
    ProductCIMZIA (certolizumab pegol) prefilled syringe kit
    Quantity limit4 syringes/28 days (starter kit: 1 kit/180 days)
    Requirements/LimitsPA, QL (4 syringes/28 days), SP
    inv-172: CTEXLI — 90 tablets/30 days
    ProductCTEXLI (chenodiol) 250 mg
    Quantity limit90 tablets/30 days
    Requirements/LimitsPA, QL (90 tablets/30 days), SP
    inv-173: ferric citrate (Auryxia) — 360 tablets/30 days
    ProductFerric citrate (Auryxia) 1 g tablets
    Quantity limit360 tablets/30 days
    Requirements/LimitsFF, QL (360 tablets/30 days), ST
    inv-174: FOSRENOL powder packs — 90-180-120 packs/30 days depending on strength
    ProductFOSRENOL (lanthanum carbonate) powder packs
    Quantity limit90–180–120 packs/30 days depending on strength (examples listed)
    Requirements/LimitsQL varies by strength; ST may apply
    inv-175: OMVOH — 1 pen/28 days or 2 pens/28 days
    ProductOMVOH (mirikizumab) presentations
    Quantity limit1 pen/28 days or 2 pens/28 days depending on presentation
    Requirements/LimitsPA, QL per presentation, SP
    inv-176: sevelamer formulations — up to 960 tablets/30 days
    ProductSevelamer formulations (carbonate / HCl)
    Quantity limitUp to 960 tablets/30 days depending on formulation (examples show high QL values)
    NotesQL depends on packet/tablet strength
    inv-177: SKYRIZI — 1 pen/56 days or 1 cartridge/56 days
    ProductSKYRIZI (risankizumab) cartridge/pen
    Quantity limit1 pen/56 days or 1 cartridge/56 days
    Requirements/LimitsPA, QL (1 pen/56 days), SP
    inv-178: SYMPROIC — 30 tablets/30 days
    ProductSYMPROIC (naldemedine)
    Quantity limit30 tablets/30 days
    Requirements/LimitsPA, QL (30 tablets/30 days)
    inv-179: TREMFYA induction pack — 3 kits/180 days
    ProductTREMFYA induction pack (guselkumab)
    Quantity limit3 kits/180 days (induction pack)
    Requirements/LimitsPA, QL (3 kits/180 days), SP
    inv-180: TRULANCE — 30 tablets/30 days
    ProductTRULANCE (plecanatide)
    Quantity limit30 tablets/30 days
    Requirements/LimitsPA, QL (30 tablets/30 days)
    inv-181: VOWST — 12 capsules/365 days
    ProductVOWST (fecal microbiota spores)
    Quantity limit12 capsules/365 days
    Requirements/LimitsLA, PA, QL (12 capsules/365 days), SP
    inv-182: multiple antidepressants and chronic agents — various QLs
    ExamplesCitalopram and escitalopram oral solutions QL examples (e.g., 600 mls/30 days); fluoxetine up to 240 capsules/30 days
    NoteMultiple antidepressants and chronic agents list product-specific QLs
    ActionFollow the Requirements/Limits entry for each agent
    inv-183: duloxetine pellets 20 mg — 180 capsules
    ProductDuloxetine 20 mg pellets
    Quantity limit180 capsules/30 days
    Requirements/LimitsQL (180 capsules/30 days)
    inv-184: FETZIMA ER — 30 capsules
    ProductFETZIMA ER (levomilnacipran)
    Quantity limit30 capsules/30 days
    Requirements/LimitsQL (30 capsules/30 days), ST for some presentations
    inv-185: quetiapine fumarate — varies (30-90 tabs/30d)
    ProductQuetiapine fumarate (various strengths)
    Quantity limitVaries by strength (30–90 tablets/30 days)
    NotesCheck specific strength entry for exact QL
    inv-186: BELSOMRA — 30 tablets
    ProductBELSOMRA (suvorexant)
    Quantity limit30 tablets/30 days
    Requirements/LimitsQL (30 tablets/30 days), ST for some presentations
    inv-187: dextroamphetamine sulfate oral solution — 1800 mls
    ProductDextroamphetamine sulfate oral solution
    Quantity limit1800 mls/30 days
    Requirements/LimitsQL (1800 mls/30 days)
    inv-188: dexmethylphenidate ER 12hr 0.1 mg — QL (120 tablets/30 days)
    ProductDexmethylphenidate ER 12hr 0.1 mg (caps/tabs)
    Quantity limitQL (120 tablets/30 days)
    Requirements/LimitsQL (120 tablets/30 days)
    inv-189: dexmethylphenidate (Focalin XR) — QL (60 capsules/30 days)
    ProductDexmethylphenidate (Focalin XR)
    Quantity limitQL (60 capsules/30 days)
    Requirements/LimitsQL (60 capsules/30 days)
    inv-190: dextroamphetamine sulfate oral solution 5 mg/5ml — QL (1800 mls/30 days)
    ProductDextroamphetamine sulfate oral solution 5 mg/5 ml
    Quantity limitQL (1800 mls/30 days)
    Requirements/LimitsQL (1800 mls/30 days)
    inv-191: methylphenidate soln 5 mg/5ml — QL (450 mls/30 days)
    ProductMethylphenidate solution 5 mg/5 ml (Methylin)
    Quantity limitQL (450 mls/30 days)
    Requirements/LimitsQL (450 mls/30 days)
    inv-192: methylphenidate soln 10 mg/5ml — QL (900 mls/30 days)
    ProductMethylphenidate solution 10 mg/5 ml (Methylin)
    Quantity limitQL (900 mls/30 days)
    Requirements/LimitsQL (900 mls/30 days)
    inv-193: methylphenidate ER osmotic release (Concerta) 18-36 mg — QL (60 tablets/30 days)
    ProductMethylphenidate ER osmotic release (Concerta) 18–36 mg
    Quantity limitQL (60 tablets/30 days)
    Requirements/LimitsQL (60 tablets/30 days)
    inv-194: methylphenidate ER 54 mg (Concerta) — QL (30 tablets/30 days)
    ProductMethylphenidate ER 54 mg (Concerta)
    Quantity limitQL (30 tablets/30 days)
    Requirements/LimitsQL (30 tablets/30 days)
    inv-195: methylphenidate tab 5 mg (Ritalin) — QL (360 tablets/30 days)
    ProductMethylphenidate tab 5 mg (Ritalin)
    Quantity limitQL (360 tablets/30 days)
    Requirements/LimitsQL (360 tablets/30 days)
    inv-196: SUNOSI — PA, QL (30 tablets/30 days)
    ProductSUNOSI (solriamfetol)
    Quantity limitPA, QL (30 tablets/30 days)
    Requirements/LimitsPA, QL (30 tablets/30 days)
    inv-197: WAKIX — LA, PA, QL (60 tablets/30 days), SP
    ProductWAKIX (pitolisant)
    Quantity limitLA, PA, QL (60 tablets/30 days)
    Requirements/LimitsLA, PA, QL (60 tablets/30 days), SP
    inv-198: cladribine (Mavenclad) — PA, QL (various tablets/301 days)
    ProductCladribine (Mavenclad) therapy packs
    Quantity limitPA, QL (various tablets/301 days)
    Requirements/LimitsPA, QL (e.g., 8 tablets/301 days), SP
    inv-199: AVONEX kit — PA, QL (1 kit/28 days), SP
    ProductAVONEX kit (interferon beta‑1a) 30 mcg/0.5 ml
    Quantity limitPA, QL (1 kit/28 days)
    Requirements/LimitsPA, QL (1 kit/28 days), SP
    inv-200: glatiramer acetate (Copaxone) — 30 syringes/30 days
    ProductGlatiramer acetate (Copaxone) prefilled syringe 20 mg/ml
    Quantity limitQL (30 syringes/30 days)
    Requirements/LimitsQL (30 syringes/30 days), SP
    inv-201: LUMRYZ / Xyrem — 1 or 540 mls/30 days QLs
    ProductLUMRYZ / Xyrem (sodium oxybate) packs/solution
    Quantity limitLA, PA, QL (30 packets/30 days for LUMRYZ; 540 mls/30 days for Xyrem)
    Requirements/LimitsLA, PA, QL, SP
    inv-203: ZEPOSIA — PA, QL (30 capsules/30 days), SP
    ProductZEPOSIA (ozanimod)
    Quantity limitPA, QL (30 capsules/30 days)
    Requirements/LimitsPA, QL (30 capsules/30 days), SP
    inv-204: acetaminophen formulations — OTC
    ProductAcetaminophen formulations (OTC)
    Quantity limitOTC designation — no prescription QL not applicable
    NotesShown as Requirements/Limits = OTC in entries
    inv-205: butalbital-acetaminophen-caffeine — 180 tablets
    ProductButalbital‑acetaminophen‑caffeine 50‑325‑40 mg
    Quantity limit180 tablets (QL = 180 tablets/30 days)
    Requirements/LimitsQL (180 tablets/30 days)
    inv-206: buprenorphine-naloxone SL film — 60-120 films/tablets
    ProductBuprenorphine‑naloxone sublingual film/tablet (various strengths)
    Quantity limit60–120 films/tablets depending on strength
    Requirements/LimitsQL varies by strength; PA may apply
    inv-207: fentanyl transdermal patch — 15 patches
    ProductFentanyl transdermal patch 72 hr
    Quantity limit15 patches (QL = 15 patches/30 days)
    Requirements/LimitsPA, QL may apply
    inv-208: morphine sulfate ER capsules — 60 capsules
    ProductMorphine sulfate ER capsules
    Quantity limit60 capsules/30 days
    Requirements/LimitsPA, QL (60 or 90 tablets/30 days depending on entry)
    inv-209: adalimumab-aaty auto-injector kit — 1 kit/180 days or 2 pens/28 days
    ProductAdalimumab‑aaty auto‑injector kit
    Quantity limit1 kit/180 days or 2 pens/28 days depending on SKU
    Requirements/LimitsPA, QL (1 kit/180 days or 2 pens/28 days), SP
    inv-210: upadacitinib oral soln (RINVOQ LQ) — 360 mls
    ProductUpadacitinib oral solution (RINVOQ LQ)
    Quantity limit360 mls/30 days
    Requirements/LimitsLA, PA, QL (360 mls/30 days), SP

    Specialty Pharmacy and Site-of-Care Designations

    Note
    Note
    Note
    Note
    Note
    Note

    Biosimilars and Related Notes

    Note

    Definitions and Acronyms

    inv-77: Generic drug definition / specialty note
    NoteMany agents are designated 'SP' indicating specialty pharmacy dispensing; QL/PA/LA flags appear with product entries
    ActionProviders must obtain PA and follow QL/SP handling where indicated
    ContactSee member services and plan documents for prior authorization processes
    inv-78: PA / QL / ST / SP acronyms
    PAPrior Authorization — plan requires approval before drug is covered
    QLQuantity Limit — maximum quantity allowed per stated time period (e.g., 30 tablets/30 days)
    SPSpecialty — indicates specialty drug handling or specialty pharmacy program
    inv-79: QL definition
    QL definitionQuantity Limit — maximum quantity allowed per time period as listed next to the product (e.g., QL (60 tablets/30 days))
    UsageDisplayed inline in Requirements/Limits for each product
    ConsequenceExceeding the QL without authorization may result in denial
    inv-80: PA definition
    PA definitionPrior Authorization — authorization required before coverage; failure to obtain PA may result in denial
    When usedPA appears in Requirements/Limits next to many specialty and high‑cost agents
    Provider actionSubmit required documentation and request PA prior to dispensing
    inv-81: LA definition
    LA definitionLA — Limited Access (restricted distribution or coverage conditions noted in Requirements/Limits)
    ImplicationLA often accompanies PA and SP for specialty distribution
    ActionFollow plan's LA pathway when LA flag is present
    inv-82: SP definition
    SP definitionSpecialty — indicates specialty drug handling and specialty pharmacy dispensing (SP)
    ImplicationSP items often require PA and have QLs; dispensed via specialty pharmacy
    ExamplesMany biologics and high-cost agents are flagged SP in the formulary
    inv-83: ACA definition (vaccines/ACA-mandated coverage)
    ACA definitionACA — preventive or ACA‑mandated coverage (often applied to vaccines)
    ExamplesVaccines such as varicella, pneumococcal, cholera listed with Requirements/Limits = ACA
    ImplicationACA flag indicates coverage under preventive mandates where applicable
    inv-84: PA (Prior Authorization) definition
    PA short labelPA = Prior Authorization
    QL short labelQL = Quantity Limit
    SP short labelSP = Specialty
    inv-85: QL (Quantity Limit) definition
    QL short labelQL = Quantity Limit (maximum allowed per time period)
    ExampleShown as QL (number/unit time) next to products
    EnforcementExceeding QL risks denial unless authorized
    inv-86: SP (Specialty) definition
    SP short labelSP = Specialty — specialty pharmacy required/used
    ImplicationSpecialty handling, PA and QL common
    ExamplesBiologics and complex agents listed with SP flag

    Step Therapy Requirements and Starter Packs

    Policy noteDetails
    Step Therapy may be enforced for certain drugs
    ST (Step Therapy) requires members to try specified preferred agents first (fail‑first) before coverage of alternative agents is allowed; exceptions may be requested per plan rules.
    Drug / FlagProgram-level restrictions
    APRETUDE
    Requirements/Limits include ACA, LA, SP — indicating ACA program coverage and limited/specialty access restrictions that may affect initiation and dispensing.
    ProductStep Therapy flag
    KERENDIA (finerenone) 10 mg, 20 mg, 40 mg
    Requirements/Limits: QL (30 tablets/30 days), ST — entry indicates a step therapy requirement may apply for this product.
    ObservationImplication
    No explicit step therapy sequences provided in the excerpt
    Several agents are instead annotated with ACA, PA, LA, or QL flags; where ST is not shown, plan rules rely on those other utilization controls and any step requirements would be listed elsewhere in the full policy.
    ProductStep Therapy note
    ferric citrate (Auryxia) tab 1 g
    Requirements/Limits: FF, QL (360 tablets/30 days), ST — listed with ST indicating step therapy applies.
    ProductsST designation
    ferric citrate (Auryxia) tab 1 g
    Requirements/Limits include ST; step therapy applies to this product as listed.
    FOSRENOL (lanthanum carbonate) powder packs 750 mg / 1000 mg
    Requirements/Limits include QL and ST (e.g., QL 180 packs/30 days or 120 packs/30 days depending on strength) — entries marked ST.
    StatementSource detail
    Step therapy applies to certain products flagged 'ST' in the formulary
    Document shows products such as ferric citrate and FOSRENOL entries annotated with ST in the Requirements/Limits field; full step sequences are not provided in this excerpt.
    SummaryNotes
    Step therapy required for products flagged ST (specifics not included in excerpt)
    Multiple listed agents (examples in psychiatric and other classes) include ST in Requirements/Limits; the policy indicates a step requirement exists but does not detail the required prior agents or exception criteria in this excerpt.
    Starter/titration packListing example
    MAYZENT STARTER PACK
    Listed separately with Requirements/Limits = LA, PA, QL (7 or 12 tablets/180 days), SP — starter pack entries indicate managed initiation.
    ZEPOSIA STARTER KIT
    ZEPOSIA - ozanimod cap 0.92 mg listed with PA, QL (30 capsules/30 days), SP; starter/titration packs are listed separately where applicable.

    Background and Scope

    This formulary lists both brand‑name and generic outpatient medications and identifies utilization management controls such as Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), and Specialty (SP). The list is intended to guide prescribing and pharmacy dispensing for EmblemHealth members; for plan‑specific coverage details and cost‑sharing, refer to the member’s Certificate of Coverage or contact Member Services.